MARKET

ACAD

ACAD

ACADIA Pharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

51.61
-2.34
-4.34%
After Hours: 52.00 +0.39 +0.76% 19:55 01/26 EST
OPEN
54.17
PREV CLOSE
53.95
HIGH
54.50
LOW
51.50
VOLUME
991.56K
TURNOVER
--
52 WEEK HIGH
58.72
52 WEEK LOW
30.02
MARKET CAP
8.20B
P/E (TTM)
-30.1056
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Opthalmic Therapeutic Market Size 2020 Research Report includes Development Trends, Key Manufacturers, Competitive Analysis and Forecast to 2024
The Express Wire · 01/19 09:45
Shuman Glenn & Stecker Investigates Acadia Pharmaceuticals, Inc.
Shuman Glenn & Stecker announces that it is investigating potential shareholder claims against certain officers and directors of Acadia Pharmaceuticals, Inc. ("Acadia" or the "Company") (NYSE: ACAD). Acadia is a biopharmaceutical company focusing on the de...
BusinessWire · 01/11 15:31
Acadia Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021, at 2:00 p.m. Eastern Time, followed by a question and answer session.
Business Wire · 12/22/2020 14:00
Acadia Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021, at 2:00 p.m. Eastern Time, followed by a question and answer session.
BusinessWire · 12/22/2020 11:00
Acadia Pharmaceu Shares Up 35.7% Since SmarTrend's Buy Recommendation (ACAD)
SmarTrend identified an Uptrend for Acadia Pharmaceu (NASDAQ:ACAD) on September 18th, 2020 at $41.78. In approximately 3 months, Acadia Pharmaceu has returned 35.68% as of today's recent price of $56.68.
Comtex SmarTrend(R) · 12/22/2020 05:37
Morgan Stanley Maintains Overweight on ACADIA Pharmaceuticals, Raises Price Target to $60
Morgan Stanley maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Overweight and raises the price target from $58 to $60.
Benzinga · 12/16/2020 16:59
Is ACAD A Good Stock To Buy Now?
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of...
Insider Monkey · 12/15/2020 19:34
Cramer Weighs In On Domino's Pizza, Gilead, More
On CNBC's "Mad Money Lightning Round," Jim Cramer said Domino's Pizza, Inc. (NYSE: DPZ) is very good. He thinks it is a win because it can deliver food contactless.
Benzinga · 12/08/2020 13:35
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ACAD. Analyze the recent business situations of ACADIA Pharm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 20 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ACAD stock price target is 62.25 with a high estimate of 72.00 and a low estimate of 42.00.
EPS
Institutional Holdings
Institutions: 448
Institutional Holdings: 163.48M
% Owned: 102.83%
Shares Outstanding: 158.98M
TypeInstitutionsShares
Increased
101
10.16M
New
129
-2.31M
Decreased
87
9.59M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.91%
Pharmaceuticals & Medical Research
-0.64%
Key Executives
Chairman/Independent Director
Stephen Biggar
President
Srdjan Stankovic
Chief Executive Officer/Director
Stephen Davis
Chief Financial Officer/Executive Vice President
Elena Ridloff
Executive Vice President/General Counsel/Secretary
Austin Kim
Executive Vice President
Gudarz Davar
Executive Vice President
Michael Yang
Senior Vice President
Stephanie Fagan
Senior Vice President
Mark Schneyer
Vice President/IR Contact Officer
Mark Johnson
Senior Vice President
Ponni Subbiah
Chief Accounting Officer
James Kihara
Director
Elizabeth Garofalo
Independent Director
Julian Baker
Independent Director
Laura Brege
Independent Director
James Daly
Independent Director
Edmund Harrigan
Independent Director
Daniel Soland
  • Dividends
  • Splits
  • Insider Activity
No Data
About ACAD
ACADIA Pharmaceuticals Inc. (ACADIA) is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines to address the medical needs in central nervous system disorders. The Company's lead product, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. ACADIA’s developments are focused on pimavanserin for additional neuropsychiatric conditions, trofinetide for Rett syndrome, ACP-044 for pain management and an early-stage muscarinic receptor program.

Webull offers kinds of ACADIA Pharmaceuticals Inc. stock information, including NASDAQ:ACAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACAD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACAD stock methods without spending real money on the virtual paper trading platform.